Sensidose participated in BIO-Europe® 2016 – 22nd Annual International Partnering Conference

Sensidose has participated in the BIO-Europe® 2016, the 22nd Annual International Partnering Conference that was held November 7-9, 2016 in Cologne, Germany. At the conference, Sensidose met with several pharmaceutical companies to discuss M&A or licensing possibilities for Flexilev/Zuades and MyFID for the treatment of Parkinsons Disease as well as the use of MyFID for other indications where an individualized and fine tuned dosing is required. Flexilev/Suades is approved in 14 European countries through the mutual recognition procedure and is currently reimbursed and sold in Sweden..

Jack Spira, Chief Executive Officer of Sensidose, said: “We met with some 30 companies and had many very fruitful meetings regarding our product Flexilev/Zuades and MyFID dosing device with potential partners at this important event. We believe this to be the ideal time for partnering discussions given the approval we have in Europe and start of commercialization in Sweden. We had a high level of interest in our Company and product by a number of pharmaceutical companies and look forward to evaluating further opportunities, as we strongly believe that our innovative approach can help improve patients’ wellbeing.”